Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.
Article Details
- CitationCopy to clipboard
Jordan CL, Noah TL, Henry MM
Therapeutic challenges posed by critical drug-drug interactions in cystic fibrosis.
Pediatr Pulmonol. 2016 Oct;51(S44):S61-S70. doi: 10.1002/ppul.23505.
- PubMed ID
- 27662106 [ View in PubMed]
- Abstract
This review seeks to re-introduce cystic fibrosis (CF) clinicians to the pharmacology of drug-drug interactions among medications commonly used in CF and provide a framework for understanding these interactions among medications outside the scope of this discussion. We here focus on drugs impacted by the cytochrome P-450 (CYP450) enzyme system and on interactions involving antimicrobials, psychotropic medications, and cystic fibrosis transmembrane conductance regulator (CFTR) modulators. Particular attention is needed when prescribing rifampin, azole antifungals and the CFTR modulators, ivacaftor, and lumacaftor/ivacaftor, in combination with other medications. The complexities of these interactions provide a strong rationale for case management by pharmacists and pharmacologists as a routine part of CF care. Pediatr Pulmonol. 2016;51:S61-S70. (c) 2016 Wiley Periodicals, Inc.
DrugBank Data that Cites this Article
- Drug Enzymes
Drug Enzyme Kind Organism Pharmacological Action Actions Lumacaftor Cytochrome P450 3A4 Protein Humans NoInducerDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareIvacaftorRitonavir The metabolism of Ivacaftor can be decreased when combined with Ritonavir. IvacaftorKetoconazole The metabolism of Ivacaftor can be decreased when combined with Ketoconazole. IvacaftorNefazodone The metabolism of Ivacaftor can be decreased when combined with Nefazodone. IvacaftorItraconazole The metabolism of Ivacaftor can be decreased when combined with Itraconazole. IvacaftorClarithromycin The metabolism of Ivacaftor can be decreased when combined with Clarithromycin.